| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Tofacitinib |
| CAS | 540737-29-9 |
| Appearance | White crystalline powder |
| MF | C22H28N6O8 |
| MW | 504.497 |
| Purity | 99% |
| Shelf Life | 2 Years |
The chemical system name of tofacitib citrate is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl) -Piperidin-1-yl]-3-oxo-propionitrile citrate, a Janus kinase inhibitor developed by Pfizer in the United States. On November 6, 2012, the U.S. Food and Drug Administration (FDA) approved the substance as a drug for the treatment of moderate to severely active rheumatoid arthritis (RA) with insufficient response or intolerance to methotrexate therapy. Treatment of adult patients.
Tofacitinib is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries. It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. It is being studied for the treatment of inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
Tofacitinib is suitable for moderate to severely active rheumatoid arthritis (RA) adult patients with insufficient or intolerable methotrexate efficacy. It can be combined with methotrexate or other non-biological anti-rheumatic drugs to improve the condition (DMARD) Used in combination.
){kind=link}